Abstract
Older adults with treatment‐resistant depression who received augmentation of their existing antidepressant with aripiprazole experienced significantly greater improvement in psychological well‐being than patients who were switched to bupropion, an open‐label trial has found. Fall rates also were lower in the aripiprazole augmentation group than among patients receiving bupropion augmentation or switching. Results were published online March 3, 2023, in The New England Journal of Medicine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
